Seratrodast

Confirm delete?

Seratrodast

Zoom

Cat No: 9002014

Biochemicals - Receptor Pharmacology

Seratrodast is a potent antagonist of the thromboxane A2 (TXA2) receptor (TP), blocking specific binding of U-46619 (Item No. 16450) to guinea pig platelets with an IC50 value of 7.4 nM and platelet aggregation induced by U-44069 (Item No. 16440) with...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

?-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid

Correlated keywords:

103186-?19-?2 receptors antagonists asthma hypertension vascular diseases allergy thromboxanes A2 TXA2 TP blocking blocks binding U-46619 U46619 U 46619 U-44069 U44069 44069 cytochromes P450 CYP450s 3A 2C9/10 2C9 2C10 CYP3A CYP2C9 CYP2C10 CYP2C8 CYP2C19 animals airways tissues samples AA-2414 AA 2414 ABT001 ABT 001 A 73001 A73001 A 73001 Abbott 73001 Abbott-73001 Bronica Seratodrast

Product Overview:
Seratrodast is a potent antagonist of the thromboxane A2 (TXA2) receptor (TP), blocking specific binding of U-46619 (Item No. 16450) to guinea pig platelets with an IC50 value of 7.4 nM and platelet aggregation induced by U-44069 (Item No. 16440) with an IC50 value of 350 nM.{26820,26819} It is metabolized, in liver microsomes, by cytochrome P450 (CYP) isoforms 3A and 2C9/10, with a minor contribution from CYP2C8 and CYP2C19.{26816} Seratrodast is commonly used to study the roles of the TP receptor in animal airways and in tissue samples.{26820,26817,26818,26815}

Size	10 mg
Shipping	dry ice
CAS Number	112665-43-7
Molecular Formula	C₂₂H₂₆O₄
SMILES	OC(CCCCCC(C1=CC=CC=C1)C(C(C(C)=C2C)=O)=C(C)C2=O)=O
Molecular Weight	354,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2907.29
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.